These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21878189)

  • 1. T cell costimulation and coinhibition: genetics and disease.
    Scandiuzzi L; Ghosh K; Zang X
    Discov Med; 2011 Aug; 12(63):119-28. PubMed ID: 21878189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantigen-Harboring Apoptotic Cells Hijack the Coinhibitory Pathway of T Cell Activation.
    Yakoub AM; Schulz R; Seiffert M; Sadek M
    Sci Rep; 2018 Jul; 8(1):10533. PubMed ID: 30002409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yin-Yang of costimulation: crucial controls of immune tolerance and function.
    Nurieva RI; Liu X; Dong C
    Immunol Rev; 2009 May; 229(1):88-100. PubMed ID: 19426216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
    Schildberg FA; Klein SR; Freeman GJ; Sharpe AH
    Immunity; 2016 May; 44(5):955-72. PubMed ID: 27192563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
    Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
    J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses.
    Ueno T; Yeung MY; McGrath M; Yang S; Zaman N; Snawder B; Padera RF; Magee CN; Gorbatov R; Hashiguchi M; Azuma M; Freeman GJ; Sayegh MH; Najafian N
    Eur J Immunol; 2012 Sep; 42(9):2343-53. PubMed ID: 22733595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell costimulation and coinhibition in atherosclerosis.
    Gotsman I; Sharpe AH; Lichtman AH
    Circ Res; 2008 Nov; 103(11):1220-31. PubMed ID: 19028921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two pathways of costimulation through CD28.
    Miller J; Baker C; Cook K; Graf B; Sanchez-Lockhart M; Sharp K; Wang X; Yang B; Yoshida T
    Immunol Res; 2009 Dec; 45(2-3):159-72. PubMed ID: 19214786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The balance of immune responses: costimulation verse coinhibition.
    Subudhi SK; Alegre ML; Fu YX
    J Mol Med (Berl); 2005 Mar; 83(3):193-202. PubMed ID: 15630593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic equilibrium of B7-1 dimers and monomers differentially affects immunological synapse formation and T cell activation in response to TCR/CD28 stimulation.
    Bhatia S; Sun K; Almo SC; Nathenson SG; Hodes RJ
    J Immunol; 2010 Feb; 184(4):1821-8. PubMed ID: 20065109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
    Barach YS; Lee JS; Zang X
    Trends Mol Med; 2011 Jan; 17(1):47-55. PubMed ID: 20971039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension.
    Vinh A; Chen W; Blinder Y; Weiss D; Taylor WR; Goronzy JJ; Weyand CM; Harrison DG; Guzik TJ
    Circulation; 2010 Dec; 122(24):2529-37. PubMed ID: 21126972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The B7 family and cancer therapy: costimulation and coinhibition.
    Zang X; Allison JP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5271-9. PubMed ID: 17875755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.
    Riley JL; June CH
    Blood; 2005 Jan; 105(1):13-21. PubMed ID: 15353480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles.
    Wingren AG; Parra E; Varga M; Kalland T; Sjogren HO; Hedlund G; Dohlsten M
    Crit Rev Immunol; 2017; 37(2-6):463-481. PubMed ID: 29773030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD28 Costimulation: From Mechanism to Therapy.
    Esensten JH; Helou YA; Chopra G; Weiss A; Bluestone JA
    Immunity; 2016 May; 44(5):973-88. PubMed ID: 27192564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costimulation, coinhibition and cancer.
    Inman BA; Frigola X; Dong H; Kwon ED
    Curr Cancer Drug Targets; 2007 Feb; 7(1):15-30. PubMed ID: 17305475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costimulation requirements of induced murine systemic autoimmune disease.
    Pollard KM; Arnush M; Hultman P; Kono DH
    J Immunol; 2004 Nov; 173(9):5880-7. PubMed ID: 15494542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation.
    Friedmann-Morvinski D; Bendavid A; Waks T; Schindler D; Eshhar Z
    Blood; 2005 Apr; 105(8):3087-93. PubMed ID: 15626734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.